Entero Therapeutics EBIT

Entero Therapeutics (ENTO) currently reports a EBIT of $-9.9M as of March 2026. That compares with $-7.5M in the prior-year period — down 32.5% year over year. That is above the sector sector average of $-63M. Use the charts on this page to explore Entero Therapeutics's EBIT history and peer comparisons.

Entero Therapeutics's EBIT decreased from $-7.5M to $-9.9M — a 32.5% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Entero Therapeutics's EBIT of $-9.9M is higher than the its sector sector average of $-63M. That is roughly 84.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Entero Therapeutics reported $-9.9M in EBIT as of March 2026. That compares with $-7.5M in the prior-year period — down 32.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-9.9M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-63M. From there, open related valuation or income-statement pages for Entero Therapeutics, and consider following ENTO for alerts when major investors trade the stock.